Investor Overview

Corporate Profile
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in refractory indolent Non-Hodgkin’s Lymphoma (iNHL) and is currently being evaluated in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib and VS-4718, and dual PI3K/mTOR inhibitor VS-5584. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.94
Change (%) Stock is Up 0.07 (3.74%)
Volume194,401
Data as of 04/28/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
04/03/17Verastem to Present at the 16th Annual Needham Healthcare Conference
BOSTON--(BUSINESS WIRE)--Apr. 3, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4th at 3:00 p.m. ET at The Westin Grand Central in New York City. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. An archived presentat... 
Printer Friendly Version
04/02/17Data on Verastem’s Focal Adhesion Kinase Inhibitor Defactinib Presented at the 2017 American Association for Cancer Research Annual Meeting
BOSTON--(BUSINESS WIRE)--Apr. 2, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of data for its lead focal adhesion kinase (FAK) inhibitor, defactinib, by the Company’s scientific collaborator David G. DeNardo, PhD, Assistant Professor of Medicine, Division of Oncology, Department of Immunology, Washington University School of Medicine in St. Louis, at the 2017 ... 
Printer Friendly Version
03/23/17Verastem Reports Year-End 2016 Financial Results
BOSTON--(BUSINESS WIRE)--Mar. 23, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the year ended December 31, 2016, and also provided an overview of certain corporate developments. “2016 was a year of significant achievement for Verastem with the in-licensing of duvelisib, a late-stage, clinical product candidate with broad potential across B-cell and T... 
Printer Friendly Version
03/16/17Verastem to Host Conference Call on March 23rd to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights
BOSTON--(BUSINESS WIRE)--Mar. 16, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will host a conference call and webcast on Thursday, March 23, 2017 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2016. The call can be accessed by dialing (877) 341-5660 (U.S. and Canada) or (315... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.